Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galen Limited
The performances of the leading medtechs in the first year of the COVID-19 pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management skills and planning.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
New OTC products and campaigns for the hay fever season from: GSK, Novartis, Dermapharm, Galenpharma, DHU and Thea Pharma.
- Contract Research, Toxicology Testing-CRO
- Generic Drugs
- Specialty Pharmaceuticals